Search results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced that Phillip A. Sharp, Ph.D., is retiring from the Company’s Board of Directors. Dr. Dr. Sharp, a Nobel Laureate, co-founded the company in 1978 and has served as a director since 1982.
Phillip Allen Sharp (born June 6, 1944) is an American geneticist and molecular biologist who co-discovered RNA splicing.
Aug 18, 2015 · Biogen’s Phillip A. Sharp Building on Binney Street opened in 2014. Since then Biogen, now worth more than $90 billion, has become a leader in therapies for MS, hemophilia, and other genetic...
Nov 11, 2022 · One of the first biotechnology companies, he said, Biogen has had the “perseverance” to go after tough diseases. He has known many of the board members, as well as Biogen founder Phil Sharp...
May 24, 2023 · Scientist Stories: Phil Sharp, Co-Founder of Biogen and Discovering RNA Splicing. Top builders in biotech. May 24, 2023. Share. Axial: https://linktr.ee/axialxyz. Axial partners with great founders and inventors.
- Axial
Phillip A. Sharp, an Institute Professor emeritus at MIT, is a member of the Department of Biology and the Koch Institute for Integrative Cancer Research. He joined the Center for Cancer Research in 1974, serving as director from 1985 to 1991 before becoming head of the Department of Biology for eight years.
People also ask
Who is Phillip Sharp?
Who is John Sharp?
How many papers has David Sharp authored?
Is running Biogen a tough job?
In 1978 — just a year after the first paper on splicing was published — Sharp and others founded Biogen, a Cambridge, Massachusetts–based biotech company. He remained on the company’s board for 29 years and helped lead work that translated the science of RNA splicing into therapeutics.
